Vericel Q2 revenue $45.9M (+24% YoY); raises FY2023 guidance to $190-197M

Vericel Corp

2023-Q2 EPS reported -$0.26 revenue$86,939,000

Total net revenue $45.9M (+24% YoY); MACI $36.3M (+27%), Epicel $9.6M (+17%).
Net loss $5.0M ($0.11 EPS) improved from $9.0M loss in Q2 2022; adjusted EBITDA $4.4M.
Full-year 2023 revenue guidance raised to $190-197M from prior $184-192M; gross margin guidance high-60% maintained.
MACI arthroscopic delivery program on track for 2024 commercial launch; human factors study planned Q3.
Extended exclusive supply agreement with Matricel GmbH for MACI collagen membrane.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.